VPTD.F Stock Overview
A medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Ventripoint Diagnostics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.11 |
| 52 Week High | CA$0.27 |
| 52 Week Low | CA$0.086 |
| Beta | 0.39 |
| 11 Month Change | 0% |
| 3 Month Change | -23.18% |
| 1 Year Change | 1.95% |
| 33 Year Change | -61.91% |
| 5 Year Change | 52.78% |
| Change since IPO | -94.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| VPTD.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 6.4% | 1.5% | 2.2% |
| 1Y | 1.9% | 20.9% | 31.7% |
Return vs Industry: VPTD.F underperformed the US Medical Equipment industry which returned 21.4% over the past year.
Return vs Market: VPTD.F underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| VPTD.F volatility | |
|---|---|
| VPTD.F Average Weekly Movement | 14.3% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VPTD.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VPTD.F's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Hugh MacNaught | ventripoint.com |
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models.
Ventripoint Diagnostics Ltd. Fundamentals Summary
| VPTD.F fundamental statistics | |
|---|---|
| Market cap | US$15.06m |
| Earnings (TTM) | -US$3.59m |
| Revenue (TTM) | US$51.56k |
303.3x
P/S Ratio-4.4x
P/E RatioIs VPTD.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VPTD.F income statement (TTM) | |
|---|---|
| Revenue | CA$72.07k |
| Cost of Revenue | CA$6.75k |
| Gross Profit | CA$65.32k |
| Other Expenses | CA$5.09m |
| Earnings | -CA$5.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.031 |
| Gross Margin | 90.64% |
| Net Profit Margin | -6,966.13% |
| Debt/Equity Ratio | -46.1% |
How did VPTD.F perform over the long term?
See historical performance and comparison